Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Study offers fresh insight into racial disparities in prostate cancer

Among patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving abiraterone acetate (Zytiga) plus prednisone, survival outcomes were similar between Black and White men, while Black men trended toward higher declines in PSA and time to PSA progression (TTP), according to outcomes from a race-stratified prospective study.1,2

Several other key findings emerged from the trial, including higher treatment toxicity in Black men and the identification of a potential biomarker of ancestry‐dependent treatment outcomes.

Read the full article here. 

source: Jason M. Broderick - Urology Times